Cambrex appoints Troy Player as President, Early Stage Development & Testing Business Unit

Troy Player

Cambrex, the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that Troy Player has been appointed as President, Early Stage Development and Testing (ESDT).

In his new role, he has responsibility for operations at the Agawam, Massachusetts; Durham, North Carolina; Edinburgh, UK; High Point, North Carolina and Longmont, Colorado facilities.

With more than 25 years of experience in senior strategic and operational executive roles, Mr Player has a proven track record of developing, driving and managing business improvement.

He joins Cambrex from West Pharmaceuticals where he spent 17 years and was most recently Vice President and General Manager of the Contract Manufacturing Business Unit where he oversaw six manufacturing locations and two engineering development centres.

Prior to this he was Vice President and Managing Director for their Asia Pacific Region. He holds a Master of Business Administration from Francis Marion University, and a Bachelor of Science in Mechanical Engineering from the University of South Carolina.

β€œI am pleased to welcome an operational excellence and continuous improvement expert like Troy to our team,” commented Shawn Cavanagh, President and Chief Operating Officer at Cambrex.

β€œHe is well-versed in leading cross-functional business improvement within commercial, manufacturing, customer service, business development, logistics/procurement, and product management/development environments, which makes him an invaluable asset to our team.”

The ESD&T Business Unit was integrated into the Cambrex service portfolio following the acquisition of Avista Pharma Solutions in January 2019.

Companies